Published in
BioMed Central, Breast Cancer Research, 6(15), 2013
DOI: 10.1186/bcr3572
Links
- ORCID
- ORCID
- BioMed Central | PDF
- ORCID
- [breast-cancer-research.com] | PDF
- [hdl.handle.net]
- [www.ncbi.nlm.nih.gov] | PDF
- [hdl.handle.net]
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [breast-cancer-research.biomedcentral.com] | PDF
- [roderic.uv.es] | PDF
Tools
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis
,
Miguel Martín,
Miguel Mart{́ı}n,
John R. Mackey,
Ana Lluch ,
Joaquín Gavila,
Charles Vogel,
Álvaro Rodríguez-Lescure,
Manuel Ruiz-Borrego,
Lourdes Calvo ,
Tadeusz Pienkowski,
Alvaro Rodríguez-Lescure,
Miguel Ángel Seguí,
Olivier Tredan
and other authors.
Full text: Download
Abstract
Abstract Introduction Obesity is an unfavorable prognostic factor in breast cancer (BC) patients regardless of menopausal status and treatment received. However, the association between obesity and survival outcome by pathological subtype requires further clarification. Methods We performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003–02, and BCIRG 001) evaluating anthracyclines and taxanes as adjuvant treatments. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differences of such prognostic effects by subtype. Results Multivariate survival analyses adjusting for age, tumor size, nodal status, menopausal status, surgery type, histological grade, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, chemotherapy regimen, and under-treatment showed that obese patients (BMI 30.0 to 34.9) had similar prognoses to that of patients with a BMI